Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 5/20 | 1.00 |
| ▸ | CLK1 | P49759 | 4/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 4/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 3/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 3/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 3/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 3/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | MAOB | P27338 | 3/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 2/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 0.62 |
| ▸ | MAOA | P21397 | 3/20 | 0.62 |
| ▸ | PIM1 | P11309 | 8/20 | 0.62 |
| ▸ | CLK2 | P49760 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416224 | 1.00 | CISD1 (1.00) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL668617 | 1.00 | CISD1 (1.00) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL668616 | 1.00 | CISD1 (1.00) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2883203 | 0.87 | CLK1 (0.77) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL497028 | 0.87 | CISD1 (0.77) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL497027 | 0.87 | CISD1 (0.77) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2883201 | 0.87 | CLK1 (0.77) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2882802 | 0.83 | PIM1 (0.79) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2882800 | 0.83 | PIM1 (0.79) | CISD1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL1808883 | 0.82 | CLK1 (0.69) | CISD1CLK1DYRK1APIK3CDCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028920-A | Method for treating hematological cancer | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260102500-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING | SMARTDYELIVERY GMBH (DE) | 2026-04-16 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250268913-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH CTM TARGETING | SMARTDYELIVERY GMBH (DE) | 2025-08-28 | — | — | US | claimed |
| WO-2025096405-A1 | METHODS OF TREATING BLOOD CANCERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-03 | — | — | US | claimed |
| EP-4512480-A2 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20220372580-A1 | MACHINE LEARNING TECHNIQUES FOR ESTIMATING TUMOR CELL EXPRESSION IN COMPLEX TUMOR TISSUE | BOSTONGENE CORPORATION (US) | 2022-11-24 | — | — | US | claimed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | claimed |
| EP-4062917-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| WO-2022159787-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220193056-A1 | COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS | CASE WESTERN RESERVE UNIVERSITY | 2022-06-23 | — | — | US | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-11246907-B2 | Immunosuppressive agents and their use in therapy | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2022-02-15 | — | — | US | claimed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | DNMT1, DNMT3B, DNMT3A | CISD1 1879/4885CLK1 3487/4885DYRK1A 3553/4885 |
| US-20260102500-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING | PRKCE, PRKCI, PRKCZ | CISD1 1307/4885CLK1 30/4885DYRK1A 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.